In Vivo Myogenic Potential of Human CD133+ Muscle-derived Stem Cells: A Quantitative Study

dc.creatorNegroni, Elisa
dc.creatorRiederer, Ingo
dc.creatorChaouch, Soraya
dc.creatorBelicchi, Marzia
dc.creatorRazini, Paola
dc.creatorDi Santo, James
dc.creatorTorrente, Yvan
dc.creatorButler-Browne, Gillian S.
dc.creatorMouly, Vincent
dc.date2018-08-16T16:49:38Z
dc.date2018-08-16T16:49:38Z
dc.date2009
dc.date.accessioned2023-09-26T22:57:18Z
dc.date.available2023-09-26T22:57:18Z
dc.identifierNEGRONI, Elisa; et al. In Vivo Myogenic Potential of Human CD133+ Muscle-derived Stem Cells: A Quantitative Study. Molecular Therapy, v.17, n.10, p.1771–1778, oct. 2009.
dc.identifier1525-0016
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/28192
dc.identifier10.1038/mt.2009.167
dc.identifier1525-0024
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8885164
dc.descriptionIn recent years, numerous reports have identified in mouse different sources of myogenic cells distinct from satellite cells that exhibited a variable myogenic potential in vivo. Myogenic stem cells have also been described in humans, although their regenerative potential has rarely been quantified. In this study, we have investigated the myogenic potential of human muscle–derived cells based on the expression of the stem cell marker CD133 as compared to bona fide satellite cells already used in clinical trials. The efficiency of these cells to participate in muscle regeneration and contribute to the renewal of the satellite cell pool, when injected intramuscularly, has been evaluated in the Rag2−/− γC−/− C5−/− mouse in which muscle degeneration is induced by cryoinjury. We demonstrate that human muscle–derived CD133+ cells showed a much greater regenerative capacity when compared to human myoblasts. The number of fibers expressing human proteins and the number of human cells in a satellite cell position are all dramatically increased when compared to those observed after injection of human myoblasts. In addition, CD133+/CD34+ cells exhibited a better dispersion in the host muscle when compared to human myoblasts. We propose that muscle-derived CD133+ cells could be an attractive candidate for cellular therapy.
dc.description2030-01-01
dc.formatapplication/pdf
dc.languageeng
dc.publisherElsevier
dc.rightsrestricted access
dc.subjectCélulas-tronco miogênicas
dc.subjectPotencial miogênico
dc.subjectin vivo
dc.subjectCD133
dc.subjectEstudo quantitativo
dc.subjectTerapia celular
dc.subjectHuman CD133+ Muscle-derived Stem Cell
dc.subjectMyogenic stem cells
dc.subjectIn Vivo
dc.subjectQuantitative study
dc.subjectCellular therapy
dc.titleIn Vivo Myogenic Potential of Human CD133+ Muscle-derived Stem Cells: A Quantitative Study
dc.typeArticle


Este ítem pertenece a la siguiente institución